News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
May 18, 2021
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of ConcernMar 24, 2021
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine CandidateFeb 23, 2021
Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C FinancingFeb 01, 2021
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The LancetFeb 01, 2021
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine CandidateDec 04, 2020
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine CandidatesNov 03, 2020
CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensureSep 25, 2020
Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine ProgramSep 25, 2020
Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine CandidateJul 08, 2020
CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate
